Search

everythinglearnresearchcommunity

for

Search:↓

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Cell transplantation faces challenges in genitourinary reconstruction, but alternative tissue sources and microencapsulation show promise.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.

Biomaterials with MSC-derived substances could improve tissue repair and have advantages over direct cell therapy.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Stem cell niches are adaptable and key for tissue maintenance and repair.

Fat cells are important for tissue repair and stem cell support in various body parts.

Cell aging can be both good and bad for tissue repair.

Soy isoflavones can protect lung tissue from radiation damage.

Higher DKK-1 levels found in hair loss patients; L-ascorbic acid 2-phosphate, L-threonate, and ginsenoside F2 may help promote hair growth.

Biomaterials combined with stem cells show promise for improving tissue repair and medical treatments.

Tissue-derived extracellular vesicles are crucial for cancer diagnosis, prognosis, and treatment.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Older age and prostatic hyperplasia in males increase the risk of hemorrhagic cystitis after stem cell transplantation.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

Medical treatments for benign prostatic hyperplasia mainly relieve symptoms, while surgery is more effective but not always suitable for elderly patients.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Dutasteride may help shrink prostate cancer tumors.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.